Update on Research & Clinical Trials


Huntington Disease Pipeline Assessment: Clinical Trials, Drug Development by Stages, Target, Mechanism of Action (MOA), RoA, Molecule Type and Key Players (2023 Update) by DelveInsight

Published October 19, 2023

“DelveInsight’s, “Huntington’s Disease Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.”

To Read The Full Article: https://www.digitaljournal.com/pr/news/getnews/huntington-disease-pipeline-assessment-clinical-trials-drug-development-by-stages-target-mechanism-of-action-moa-roa-molecule-type-and-key-players-2023-update-by-delveinsight#ixzz8GoKx10Gm